Gastric pentadecapeptide BPC 157 counteracts morphine-induced analgesia in mice.
Boban Blagaic. A A; Turcic. P P; Blagaic. V V; Dubovecak. M M; Jelovac. N N; Zemba. M M; Radic. B B; Becejac. T T; Stancic Rokotov. D D; Sikiric. P P
Key Findings
- BPC‑157 (10 pg‑10 µg/kg i.p.) reverses morphine‑induced analgesia after about 30 minutes.
- Naloxone (10 mg/kg s.c.) quickly blocks morphine analgesia, confirming opioid involvement.
- Haloperidol enhances morphine analgesia, and BPC‑157 counteracts this enhancement.
- BPC‑157, naloxone, and haloperidol alone do not produce analgesia.
Practical Outcomes
- For biohackers, this suggests BPC‑157 may interfere with opioid pain relief and could influence dopamine‑related pathways, but the data are only in mice and at very low doses. It isn’t a useful analgesic and shouldn’t be added to protocols for pain management or performance without human evidence. If you’re exploring opioid tolerance or dopamine modulation, note that BPC‑157 might blunt opioid effects, but more research is needed before any real‑world use.
Summary
In mice, the peptide BPC‑157 was found to reverse the pain‑blocking effect of morphine, acting through the brain's dopamine system. It didn't produce pain relief on its own, but it stopped both morphine's effect and the extra boost that a dopamine blocker (haloperidol) gave to morphine.
Abstract
Previously, the gastric pentadecapeptide BPC 157, (PL 14736, Pliva) has been shown to have several beneficial effects, it exert gastroprotective, anti-inflammatory actions, stimulates would healing and has therapeutic value in inflammatory bowel disease. The present study aimed to study the effect of naloxone and BPC 157 on morphine-induced antinociceptive action in hot plate test in the mouse. It was found that naloxone and BPC 157 counteracted the morphine (16 mg/kg s.c.) - analgesia. Naloxone (10 mg/kg s.c.) immediately antagonised the analgesic action and the reaction time returned to the basic values, the development of BPC 157-induced action (10 pg/kg, 10 ng/kg, 10 microg/kg i.p.) required 30 minutes. When haloperidol, a central dopamine-antagonist (1 mg/kg i.p.), enhanced morphine-analgesia, BPC 157 counteracted this enhancement and naloxone reestablished the basic values of pain reaction. BPC 157, naloxone, and haloperidol per se failed to exert analgesic action. In summary, interaction between dopamine-opioid systems was demonstrated in analgesia, BPC 157 counteracted the haloperidol-induced enhancement of the antinociceptive action of morphine, indicating that BPC acts mainly through the central dopaminergic system.
Study Information
pubmed
2009